Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study.
Gray KJ, Bordt EA, Atyeo C, Deriso E, Akinwunmi B, Young N, Baez AM, Shook LL, Cvrk D, James K, De Guzman R, Brigida S, Diouf K, Goldfarb I, Bebell LM, Yonker LM, Fasano A, Rabi SA, Elovitz MA, Alter G, Edlow AG. · 2021
Read Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. by Gray KJ, Bordt EA, Atyeo C, Deriso E, Akinwunmi B, Young N, Baez AM, Shook LL, Cvrk D, James K, De Guzman R, Brigida S, Diouf K, Goldfarb I, Bebell LM, Yonker LM, Fasano A, Rabi SA, Elovitz MA, Alter G, Edlow AG. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7997025.txt.
Introduction
Gray and co-authors report a cohort study of COVID-19 vaccine response in pregnant and lactating women. These women were left out of the first vaccine trials. That gap left them to decide without data. The team enrolled 131 women of childbearing age at two academic centres. Most were pregnant or breastfeeding; a small group was neither. Blood and breast milk were tested across the vaccine course.
Vaccine-driven antibody levels matched those in the nonpregnant group. Levels also topped those seen after natural infection in pregnancy. Antibodies reached the umbilical cord blood of babies delivered in the study window. Blocking power was confirmed in a subset of samples. Side effects after the shots were gathered by questionnaire. The study gives this group the direct evidence the trials had skipped.
Catalog record
| CREATOR | Gray KJ, Bordt EA, Atyeo C, Deriso E, Akinwunmi B, Young N, Baez AM, Shook LL, Cvrk D, James K, De Guzman R, Brigida S, Diouf K, Goldfarb I, Bebell LM, Yonker LM, Fasano A, Rabi SA, Elovitz MA, Alter G, Edlow AG. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study By Kathryn J. Gray, Evan A. Bordt, Caroline Atyeo, Elizabeth Deriso, Babatunde Akinwunmi, Nicola Young, Aranxta Medina Baez, Lydia L. Shook, Dana Cvrk, Kaitlyn James, Rose De Guzman, Sara Brigida Published in: American Journal of Obstetrics and Gynecology DOI: 10.1016/j.ajog.2021.03.023 ABSTRACT Background Pregnant and lactating women were excluded from initial coronavirus disease 2019 vaccine trials; thus, data to guide vaccine decision making are lacking. Objective This study aimed to evaluate the immunogenicity and reactogenicity of coronavirus disease 2019 messenger RNA vaccination in pregnant and lactating women compared with: (1) nonpregnant controls and (2) natural coronavirus disease 2019 infection in pregnancy. Study Design A total of 131 reproductive-age vaccine recipients (84 pregnant, 31 lactating, and 16 nonpregnant women) were enrolled in a prospective cohort study at 2 academic medical centers. Titers of severe acute respiratory syndrome coronavirus 2 spike and receptor-binding domain immunoglobulin G, immunoglobulin A, and immunoglobulin M were quantified in participant sera (n=131) and breastmilk (n=31) at baseline, at the second vaccine dose, at 2 to 6 weeks after the second vaccine, and at delivery by Luminex. Umbilical cord sera (n=10) titers were assessed at delivery. Titers were compared with those of pregnant women 4 to 12 weeks from the natural infection (n=37) by enzyme-linked immunosorbent assay. A pseudovirus neutralization assay was used to quantify neutralizing antibody titers for the subset of women who delivered during the study period. Postvaccination symptoms were assessed via questionnaire. Kruskal-Wallis tests and a mixed-effects model, with correction for multiple comparisons, were used to assess differences among groups. Results Vaccine-induced antibody titers were equivalent in pregnant and lactating compared with nonpregnant women (pregnant, median, 5.59; interquartile range, 4.68–5.89; lactating, median, 5.74; interquartile range, 5.06–6.22; nonpregnant, median, 5.62; interquartile range, 4.77–5.98, P=.24). All titers were significantly higher than those induced by severe acute respiratory syndrome coronavirus 2 infection during pregnancy (P<.0001). Vaccine-generated antibodies were present in all umbilical cord blood and breastmilk samples. Neutralizing antibody titers were lower in umbilical cord than maternal sera, although this finding did not achieve statistical significance (maternal sera, median, 104.7; interquartile range, 61.2–188.2; cord sera, median, 52.3; interquartile range, 11.7–69.6; P=.05). The second vaccine dose (boost dose) increased severe acute respiratory syndrome coronavirus 2–specific immunoglobulin G, but not immunoglobulin A, in maternal blood and breastmilk. No differences were noted in reactogenicity across the groups. Conclusion Coronavirus disease 2019 messenger RNA vaccines generated robust humoral immunity in pregnant and lactating women, with immunogenicity and reactogenicity similar to that observed in nonpregnant women. Vaccine-induced immune responses were statistically significantly greater than the response to natural infection. Immune transfer to neonates occurred via placenta and breastmilk. INTRODUCTION More than 73,600 infections and 80 maternal deaths have occurred in pregnant women in the United States alone as of March 1, 2021.1 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is more severe in pregnant women compared with their nonpregnant counterparts, with an increased risk of hospital admission, intensive care unit stay, and death.2 Despite their higher risk, pregnant and lactating women were not included in any initial coronavirus disease 2019 (COVID-19) vaccine trials, although the first vaccine trial began in pregnant women in February 2021 (Pfizer/BioNTech, ClinicalTrials.gov identifier: NCT04754594).AJOG at a GlanceWhy was this study conducted?Because pregnant and lactating women were excluded from initial coronavirus disease 2019 (COVID-19) vaccine trials, data are lacking regarding vaccine efficacy and infant humoral protection in this population.Key findingsPregnant and lactating women elicited comparable vaccine-induced humoral immune responses with nonpregnant controls and generated higher antibody titers than those observed after severe acute respiratory syndrome coronavirus 2 infection in pregnancy. Vaccine-generated antibodies were present in umbilical cord blood and breastmilk after maternal vaccination.What does this add to what is known?This study provides data from a large cohort on maternal antibody generation in response to COVID-19 vaccination, compares vaccine-generated immunity with that from natural infection in pregnancy, and suggests that vaccination of pregnant and lactating women can confer robust maternal and neonatal immunity. The COVID-19 pandemic has given rise to hundreds of vaccine platforms in development to fight SARS-CoV-2.3 , 4 However, few of these platforms have been tested or are specifically designed to elicit immunity in vulnerable populations, including pregnant women. Pregnant women have long been left out of therapeutic and vaccine research, reportedly owing to heightened safety concerns in this population.5, 6, 7, 8 Although the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine encouraged the Food and Drug Administration to include pregnant women in the COVID-19 vaccine emergency use authorization (EUA) owing to the risk of increased disease severity in this population, evidence about vaccine immunogenicity to guide patient decision making and provider counseling is lacking.10, 11, 9 In particular, given the novelty of the first emergency approved COVID-19 vaccines, both of which use messenger RNA (mRNA) to deliver SARS-CoV-2 spike to educate the immune system,12 , 13 it remains unclear whether this novel vaccine approach will drive immunity in the context of pregnancy and whether antibodies will be transferred efficiently to neonates via the cord and breastmilk. Here, vaccine-induced immunity was profiled in vaccinated pregnant, lactating, and nonpregnant controls compared with women infected with SARS-CoV-2 during pregnancy. MATERIALS AND METHODS Study design Women at 2 tertiary care centers were approached for enrollment in an institutional review board–approved COVID-19 pregnancy and lactation biorepository study between December 17, 2020, and February 23, 2021. Eligible women were: (1) pregnant, (2) lactating, or (3) nonpregnant and of reproductive age (18–45 years), 18 years old, able to provide an informed consent, and receiving the COVID-19 vaccine. Participants and procedures Eligible study participants were identified by practitioners at the participating hospitals or were self-referred. A study questionnaire was administered to assess pregnancy and lactation status, previous SARS-CoV-2 infection, timing of COVID-19 vaccine doses, type of COVID-19 vaccine received (BNT162b2 Pfizer/BioNTech or mRNA-1273 Moderna/National Institutes of Health [NIH]), and side effects after each vaccine dose (injection site soreness, injection site skin reaction or rash, headache, myalgias, fatigue, fever or chills, allergic reaction, or others [reaction detailed]). A cumulative symptom and reactogenicity score was generated by assigning 1 point to each side effect. Sample collection and processing Blood and breastmilk from lactating women were collected at V0 (at the time of the first vaccine dose/baseline), at V1 (at the time of the second vaccine dose/“prime” profile), at V2 (2–6 weeks after the second vaccine dose/“boost” profile), and at delivery (for pregnant participants who delivered during the study time frame). Umbilical cord blood was also collected at delivery for pregnant participants. The V2 time point reflects full antibody complement, achieved 1 week after Pfizer/BioNTech and 2 weeks after Moderna/NIH.12 , 13 Blood was collected by venipuncture (or from the umbilical vein following delivery for cord blood) into serum separator tubes. Blood was centrifuged at 1000 g for 10 min at room temperature. Sera were aliquoted into cryogenic vials and stored at −80°C. Breastmilk was collected by the lactating participant into study-provided breastmilk bottles or breastmilk bags depending on volume. Breastmilk was centrifuged at 2000 rpm at 4°C for 25 minutes, supernatant was aliquoted into cryogenic vials and stored at −80°C. Antibody quantification Antibody quantification was performed as described